Lorraine Wilson, MD
Nephrology · Oklahoma City, OKNPI 1720180029
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AstraZeneca at 31.1% of the total. Reporting peaked in 2024 at $1,469 and has fallen 92.3% since, to $113 in 2025.
Across 194 payments — averaging $26.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Vifor Pharma, Inc.$474
- Amgen$455
- Travere Therapeutics, Inc.$351
- Novartis$315
- Fresenius USA Marketing, Inc.$298
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,76794%
- Education$2796%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 67 | $1,570 |
| Vifor Pharma, Inc. | 18 | $474 |
| Amgen | 11 | $455 |
| Travere Therapeutics, Inc. | 12 | $351 |
| Novartis | 12 | $315 |
| Fresenius USA Marketing, Inc. | 18 | $298 |
| Aurinia Pharma U.S., Inc. | 6 | $272 |
| Otsuka America Pharmaceutical, Inc. | 8 | $210 |
| Nxstage Medical, Inc. | 3 | $154 |
| Calliditas Therapeutics US Inc. | 2 | $145 |
| Bard Peripheral Vascular, Inc. | 1 | $142 |
| Boehringer Ingelheim | 6 | $119 |
| Ardelyx, Inc. | 6 | $114 |
| OPKO Pharmaceuticals, LLC | 5 | $96 |
| Bayer | 5 | $88 |
| Lilly USA, LLC | 4 | $70 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $34 |
| Mallinckrodt Enterprises LLC | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $24 |
| GSK | 1 | $22 |
| Akebia Therapeutics Inc | 1 | $21 |
| Pfizer | 1 | $17 |
| Cormedix Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,046 in reported general payments places this provider in the 70th percentile of 106 nephrology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 394 | $394,920 |
| JardianceEmpagliflozin | 125 | $156,417 |
| VelphoroSucroferric Oxyhydroxide | 11 | $77,597 |
| VeltassaPatiromer Calcium Sorbitex | 43 | $46,442 |
| KerendiaFinerenone | 40 | $42,160 |
| LokelmaSodium Zirconium Cyclosilicate | 28 | $25,474 |
| DapagliflozinDapagliflozin Propanediol | 21 | $13,824 |
| Nifedipine ErNifedipine | 102 | $4,570 |
| Potassium Citrate ErPotassium Citrate | 30 | $3,214 |
| Valsartan | 56 | $2,857 |
| Terazosin Hcl | 90 | $2,544 |
| Allopurinol | 162 | $1,891 |
| Calcium Acetate | 29 | $1,859 |
| Doxazosin Mesylate | 88 | $1,736 |
| Sevelamer Carbonate | 15 | $1,560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,570 | $420,394422 claims |
| Boehringer IngelheimJardiance | $119 | $156,417125 claims |
| Fresenius USA Marketing, Inc.Velphoro | $298 | $77,59711 claims |
| BayerKerendia | $88 | $42,16040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 106 nephrology providers in Oklahoma.
Other nephrology in Oklahoma City
- Celeste BoeckmanOklahoma City$90K
- Joseph GhataOklahoma City$45K
- Benjamin CowleyOklahoma City$36K
- Brad CarterOklahoma City$13K
- Laura RankinOklahoma City$11K
- Gary BondOklahoma City$9K
- Sudhir KhannaOklahoma City$7K
- Jawaid JamalOklahoma City$7K
- Patrick ReevesOklahoma City$6K
- Bradley LongOklahoma City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.